Change of platelet activation markers using flow cytometry in patients with hematology/oncology disorders after transfusion.
In spite of the frequent need of platelet transfusions, there is limited information on the association of platelet activation markers, in transfused patients with hematology/oncology disorders, with platelet function using flow cytometry. The goal of this study was to evaluate the changes of PAC-1 binding and CD62P expression, with or without agonists in patients after transfusions. Twenty-eight whole blood samples were obtained from 24 patients admitted to the department of Hematology & Oncology and transfused with platelets; these samples were compared to 30 healthy controls. Whole blood samples, either with or without agonists, such as 20 microM adenosine diphosphate (ADP) or 100 microM thrombin receptor activating peptide (TRAP), were stained with the fluorescein conjugated monoclonal antibodies PAC-1 or CD62P. Then, the percent expression for each marker was analysed using flow cytometry. ADP and TRAP induced an increased percentage of CD62P expression and PAC-1 binding after platelet transfusions compared to the samples studied before transfusion, and these findings were lower than those of the healthy controls. However, the expression of platelets without the agonists was not significantly changed, despite the transfusions. Therefore, agonist-induced platelet activation markers, studied by flow cytometry, appear to be more useful for the evaluation of platelet function after transfusions than platelet activation markers without agonists.
Lim
Young Ae
YA
Departments of Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea. limyoung@ajou.ac.kr
Cho
Sung Ran
SR
Lee
Wee Gyo
WG
Park
Joon Seong
JS
Kim
Sin Won
SW
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000097:blood* / Q000150:complications; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007938:Leukemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000032:analysis; D015539:Platelet Activation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis; D017713:Platelet Transfusion; D039341:Receptors, Fibrinogen / Q000032:analysis; D018179:Receptors, Thrombin; D013921:Thrombocytopenia / Q000097:blood* / Q000139:chemically induced / Q000209:etiology / Q000628:therapy
D000970:Antineoplastic Agents; D015415:Biomarkers; D019007:P-Selectin; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D039341:Receptors, Fibrinogen; D018179:Receptors, Thrombin; D000244:Adenosine Diphosphate